Clinical value of fucosylated Golgi protein 73 in differential diagnosis of small hepatocellular carcinoma

Zhao YunSheng; Zhang LiNa; Huo LiJing; Pei Liu; Li QiuPing; Li HongChen; Jin Liang

doi:10.3969/j.issn.1001-5256.2018.08.023

Issue 8

Aug. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(8): 1707-1711

PDF( 1717 KB)

Clinical value of fucosylated Golgi protein 73 in differential diagnosis of small hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2018.08.023

Department of Clinical Laboratory, Qinhuangdao First Hospital

Research funding:

Received Date: 2018-02-22
Published Date: 2018-08-20

Abstract

Abstract

Objective To investigate the clinical value of serum fucosylated Golgi protein 73 ( Fuc-GP73) in the differential diagnosis of small hepatocellular carcinoma ( s HCC) with a low level of alpha-fetoprotein ( AFP) . Methods A total of 110 patients who were treated in Qinhuangdao First Hospital from April to December, 2014 were enrolled, and among these patients, 50 had s HCC with a low level of AFP ( s HCC group) , 20 had chronic hepatitis B ( CHB group) , 20 had liver cirrhosis ( LC group) , and 20 had malignant tumor in the digestive system except liver cancer ( MTDS group) . A total of 40 individuals who underwent physical examination in our hospital were enrolled as normal controls ( NC group) . Lectin affinity chromatography and ELISA were used to measure the serum level of Fuc-GP73. The Kruskal-Wallis H test was used for comparison of continuous data between multiple groups, and the Nemenyi test was used for further comparison between two groups; the chi-square test was used for comparison of categorical data between groups. The receiver operating characteristic ( ROC) curve was plotted to analyze the value of Fuc-GP73 in the diagnosis of s HCC. The logistic regression model was used to evaluate the diagnostic efficiency of the combined measurement of Fuc-GP73 and other markers. Results There was a significant difference in the level of Fuc-GP73 between groups ( H = 87. 225, P = 0. 001) , and the s HCC group had a significantly higher level than the other groups ( all P <0. 05) . The detection rate of Fuc-GP73 was 80% ( 40/50) in the s HCC group, 0 ( 0/20) in the CHB group, 20% ( 4/20) in the LC group, 5% ( 1/20) in the MTDS group, and 0 ( 0/40) in the NC group; there was a significant difference between groups ( χ2= 92. 143, P< 0. 01) , and the s HCC group had a significantly higher detection rate than the other groups ( all P < 0. 01) . In the diagnosis of s HCC, Fuc-GP73 had a sensitivity of 80. 0%, a specificity of 95. 0%, an accuracy rate of 90. 0%, and an area under the ROC curve of 0. 892, and the combined measurement of Fuc-GP73 and other markers had a sensitivity of 96. 0%, a specificity of 98. 0%, an accuracy rate of97. 3%, and an area under the ROC curve of 0. 991. Conclusion Fuc-GP73 can be used as a glycosylated tumor marker for s HCC and is better than AFP.
- carcinoma, hepatocellular,
- Golgi protein 73,
- glycosylation,
- early diagnosis

FullText(HTML)

References(25)

References

[1] JEMAL A, BRAY F, CENTER MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2) :69-90.

[2]CLARK HP, CARSON WF, KAVANAGH PV, et al.Staging and current treatment of hepatocellular carcinoma[J].Radiographics, 2005, 25 (Suppl 1) :s3-s23.

[3]YAMAMOTO K, IMAMURA H, MATSUYAMA Y, et al.AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J].J Gastroenterol, 2010, 45 (12) :1272-1282.

[4]JOHNSON PJ.The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma[J].Clin Liver Dis, 2001, 5 (1) :145-159.

[5]ZHANG Q, SHAN HL, XU W.Value of serum GP73, AFP, and AFP-L3 in diagnosis of liver cancer and recurrence monitoring after radiofrequency ablation[J].J Clin Hepatol, 2015, 31 (2) :232-235. (in Chinese) 张勤, 单洪丽, 续薇.血清高尔基体糖蛋白73、甲胎蛋白及甲胎蛋白异质体3在肝癌诊断及射频消融术后复发监测中的应用价值[J].临床肝胆病杂志, 2015, 31 (2) :232-235.

[6]MIYOSHI E, MORIWAKI K, NAKAGAWA T.Biological function of fucosylation in cancer biology[J].J Biochem, 2008, 143 (6) :725-729.

[7]WU J, ZHU J, YIN H, et al.Analysis of glycan variation on glycoproteins from serum by the reverse lectin-based ELISA assay[J].J Proteome Res, 2014, 13 (4) :2197-2204.

[8]MA C, ZHANG Q, QU J, et al.A precise approach in large scale core-fucosylated glycoprotein identification with low-and highnormalized collision energy[J].J Proteomics, 2015, 114:61-70.

[9]JIANG K, LI W, ZHANG Q, et al.GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness[J].Oncotarget, 2016, 7 (17) :23530-23541.

[10]JIANG K, SHANG S, LI W, et al.Multiple lectin assays for detecting glyco-alteration of serum GP73 in liver diseases[J].Glycoconj J, 2015, 32 (9) :657-664.

[11]ZHANG S, JIANG K, SUN C, et al.Quantitative analysis of sitespecific N-glycans on sera haptoglobinβchain in liver diseases[J].Acta Biochim Biophys Sin (Shanghai) , 2013, 45 (12) :1021-1029.

[12]WEI FX, LIU Z, GENG J, et al.Research advances in association between Golgi protein 73 and liver diseases[J].J Clin Hepatol, 2017, 33 (8) :1595-1598. (in Chinese) 魏丰贤, 刘钊, 耿婕, 等.高尔基体蛋白73与肝脏疾病的关系[J].临床肝胆病杂志, 2017, 33 (8) :1595-1598.

[13]ZHAO Y, WANG M, CUI C, et al.Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma[J].Cancer Biomark, 2015, 15 (5) :677-683.

[14]BLOCK TM, COMUNALE MA, LOWMAN M, et al.Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans[J].Proc Natl Acad Sci U S A, 2005, 102 (3) :779-784.

[15]DRAKE RR, SCHWEGLER EE, MALIK G, et al.Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers[J].Mol Cell Proteomics, 2006, 5 (10) :1957-1967.

[16]Chinese Anticancer Association.New standard for diagnosis and treatment of common malignant tumors[M].Beijing:Chinese Union Medical University Press, 1999:389. (in Chinese) 中国抗癌协会.新编常见恶性肿瘤诊治规范[M].北京:中国协和医科大学出版社, 1999:389.

[17]Chinese Society of Infectious Diseases and Parasitology, Chinese Society of Hepatology, Chinese Medical Association.Prevention and treatment of viral hepatitis[J].Chin J Infect Dis, 2001, 19 (1) :56-62. (in Chinese) 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19 (1) :56-62.

[18] WANG JZ, FAN M.Protein technical manual[M].Beijing:Science Press, 1986:235-243. (in Chinese) 汪家政, 范明.蛋白质技术手册[M].北京:科学出版社, 1986:235-243.

[19]ZHAO YS, WANG M, CUI CY, et al.Clinical significance of eight serum indexes in diagnosis of primary hepatic carcinoma[J].Chongqing Med, 2014, 43 (2) :214-216. (in Chinese) 赵运胜, 王猛, 崔辰莹, 等.评价8种血清标志物在原发性肝癌诊断中的临床价值[J].重庆医学, 2014, 43 (2) :214-216.

[20]YANG SP, LI HY.Diagnostic value of AFP and GP73 test in patients with primary hepatic carcinoma[J].Chongqing Med, 2012, 41 (27) :2880-2882. (in Chinese) 杨收平, 李海英.血清AFP和高尔基体蛋白73联合检测对原发性肝癌的诊断价值[J].重庆医学, 2012, 41 (27) :2880-2882.

[21]SAFFROY R, PHAM P, REFFAS M, et al.New perspectives and strategy research biomarkers for hepatocellular carcinoma[J].Clin Chem Lab Med, 2007, 45 (9) :1169-1179.

[22]WAIDELY E, AL-YUOBI AR, BASHAMMAKH AS, et al.Serum protein biomarkers relevant to hepatocellular carcinoma and their detection[J].Analyst, 2016, 141 (1) :36-44.

[23]OZKAN H, ERDAL H, TUTKAK H, et al.Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma[J].Digestion, 2011, 83 (1-2) :83-88.

[24]KUZMANOV U, KOSANAM H, DIAMANDIS EP.The sweet and sour of serological glycoprotein tumor biomarker quantification[J].BMC Med, 2013, 11:31.

[25]MATSUMOTO H, SHINZAKI S, NARISADA M, et al.Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer[J].Clin Chem Lab Med, 2010, 48 (4) :505-512.

Relative Articles

[1]	Di WU, Dahua DAI, Wenmei LIANG, Bao FU, Xiaoyun FU. Clinical features of acute pancreatitis in pregnancy and related risk factors[J]. Journal of Clinical Hepatology, 2024, 40(5): 1009-1015. doi: 10.12449/JCH240522
[2]	Yufeng ZHENG, Xulei ZHANG, Yuhang WENG, Yongfeng YANG. Etiological spectrum and clinical features of patients with unexplained liver disease manifesting as isolated jaundice: An analysis of 91 cases[J]. Journal of Clinical Hepatology, 2023, 39(5): 1105-1109. doi: 10.3969/j.issn.1001-5256.2023.05.016
[3]	Chengsi ZHAO, Weijie YAO, Peng YUAN, Zuozheng WANG. Time distribution of risk factors for secondary pancreatic infection in acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1686-1690. doi: 10.3969/j.issn.1001-5256.2022.07.044
[4]	Ruihua ZHANG, Tingting QIN, Yueming SHAO, Yu ZHANG, Yang WANG, Xiaoyu WEN. Jaundice and portal hypertension caused by hepatic epithelioid hemangioendothelioma: A case report[J]. Journal of Clinical Hepatology, 2021, 37(7): 1662-1664. doi: 10.3969/j.issn.1001-5256.2021.07.036
[5]	Si XIE, Ming YANG, Yuan HUANG, Lai WEI. Differential diagnosis and treatment of jaundice after comprehensive treatment of advanced primary liver cancer: A case report[J]. Journal of Clinical Hepatology, 2021, 37(2): 400-402. doi: 10.3969/j.issn.1001-5256.2021.02.030
[6]	Wang CaiBin, Su Yang. Risk factors for posthepatectomy liver failure and related prevention and treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(9): 2119-2124. doi: 10.3969/j.issn.1001-5256.2020.09.048
[7]	Cao Yuan, Yao GuoXiang, Shi YiHai. An excerpt of international consensus guidelines for risk factors in chronic pancreatitis (2020)[J]. Journal of Clinical Hepatology, 2020, 36(8): 1720-1722. doi: 10.3969/j.issn.1001-5256.2020.08.008
[8]	Lei Yu, Li JiaJia, Liu RongAn, Ceng Fan, Li GuiSen, Lan YunPing. Clinical features of patients with sepsis-induced cholestatic jaundice and risk factors for death[J]. Journal of Clinical Hepatology, 2020, 36(5): 1065-1071. doi: 10.3969/j.issn.1001-5256.2020.05.023
[9]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[10]	Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041
[11]	Luo XiaoKe, Li XiaoLing, Yang LiMing, Wang XiaoHong. Efficacy of magnesium isoglycyrrhizinate in treatment of hepatitis E with severe jaundice[J]. Journal of Clinical Hepatology, 2014, 30(6): 537-539. doi: 10.3969/j.issn.1001-5256.2014.06.014
[12]	Yu Zheng, Jia JiDong. Risk factors, diagnostic criteria, and drug discontinuation criteria for drug- induced liver injury[J]. Journal of Clinical Hepatology, 2013, 29(9): 674-677. doi: 10.3969/j.issn.1001-5256.2013.09.010
[13]	Bao XuLi, Tian Zhou, Chen QingFeng, Li Li, Zhang Lei, Lu: Jun. One case of primary hepatic amyloidosis characterized by jaundice[J]. Journal of Clinical Hepatology, 2013, 29(12): 943-944. doi: 10.3969/j.issn.1001-5256.2013.12.018
[14]	Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
[15]	Chen Qian, Wen XiaoYu, Pan Yu. Jaundice due to hepatic syphilis: A case report[J]. Journal of Clinical Hepatology, 2013, 29(4): 303-304.
[16]	Yang ZongGuo, Chen XiaoRong, Lu YunFei, Liu Cheng. Decotion in chronic hepatitis B patients (damp-heat blood stasis syndrome) with low-grade jaundice[J]. Journal of Clinical Hepatology, 2012, 28(10): 771-774+784.
[17]	Shi HaiDong. Clinical observation of alprostadil injection in the treatment of liver cirrhosis with jaundice[J]. Journal of Clinical Hepatology, 2011, 27(9): 962-964.
[18]	Dou WeiJia, Zhou Lin, Wu KaiChun. Risk factors of chronic pancreatitis[J]. Journal of Clinical Hepatology, 2011, 27(11): 1180-1183.
[19]	Wang Hong, Wang YingMin, Zhang Bo. Prospective analysis of risk factors for the occurrence of hepatocellular carcinoma in patients with post-hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(1): 34-35.
[20]	Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	程玉鑫，刘亮，董适毓，李胜超，张萌. 外泌体蛋白、mRNA及非编码RNA调节肝癌发生和发展的研究进展. 实用医学杂志. 2024(06): 748-755 .
2.	王玲，曹信宇，商伟芳，丁秀婷. 慢性乙型肝炎患者外泌体miR-335-5p与肝硬化严重程度的相关性. 中国热带医学. 2024(03): 326-332 .
3.	窦金萍，高维崧，韦双，高新桃，李轶女. 外泌体MicroRNA在抗病毒免疫中的功能分析. 生物技术通报. 2024(05): 48-57 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1515) PDF downloads(318)

Clinical value of fucosylated Golgi protein 73 in differential diagnosis of small hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2018.08.023